Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 6
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Cipla Ltd, Pharmaceuticals & Healthcare, Deal Details 17
Asset Purchase 17
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17
Cipla Acquires Product Line from Camber Pharma 18
Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19
Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20
Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21
Private Equity 22
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22
FIL Capital to Invest in Cipla Health 24
Partnerships 25
Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25
MannKind to Enter into Marketing and Distribution Agreement with Cipla 26
Cipla and Roche Products Enter into Distribution Agreement 27
Cipla and Novartis May Enter into Co-Marketing Agreement 28
Cipla Enters into Distribution Agreement with BioQ Pharma 29
Cipla to Form Joint Venture with Biopharm 30
Cipla Enters into Distribution Agreement with Serum Institute 31
Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32
Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33
Cipla Enters into Distribution Agreement with Serum Institute of India 34
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35
Cipla Enters into Agreement with S&D Pharma 36
Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37
Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40
Licensing Agreements 41
Cipla Receives Rights from MSN Laboratories 41
Cipla Enters into Licensing Agreement with Stempeutics 42
Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44
Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47
Gilead Sciences Enters into Licensing Agreement with Cipla 48
Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49
Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52
Equity Offering 54
Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54
Cipla to Raise USD293.2 Million in Public Offering of Securities 55
Debt Offering 56
Cipla to Raise USD293.2 Million in Debt Offering 56
Acquisition 57
Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57
PharmaS to Acquire Cipla Croatia from Cipla Holding 58
Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59
Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60
Allergan Acquires Chase Pharma 61
Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62
Cipla Divests 25% Stake in BioMab for USD25.8 Million 63
Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64
Cipla to Acquire Duomed Produtos 65
Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66
Cipla Acquires Remaining 75% Stake in MabPharm 67
Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68
Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69
Cipla Acquires Celeris, Medical Products Distributor 70
Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For US$15 Million 71
Cipla Completes Acquisition Of Cipla Medpro South Africa For US$512 Million 72
Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74
Cipla Ltd – Key Competitors 75
Cipla Ltd – Key Employees 76
Cipla Ltd – Locations And Subsidiaries 77
Head Office 77
Other Locations & Subsidiaries 77
Recent Developments 80
Strategy And Business Planning 80
Jul 13, 2018: Cipla Opens Up To Crowd Sourcing Innovation 80
Financial Announcements 82
Nov 07, 2017: Cipla Q2 FY18 Results Demonstrate Strong Growth Across Businesses and the Benefit of Operating Leverage 82
Aug 11, 2017: Cipla Announces Q1FY 18 Results 83
May 25, 2017: Cipla announces Q4 & FY 17 results Continued strong performance across key markets 84
Corporate Communications 85
Jan 09, 2017: Cipla appoints Peter Lankau as an Independent Director on its Board 85
Legal and Regulatory 86
Apr 16, 2018: Cipla: US FDA conducted a routine current Good Manufacturing Practices (cGMP) audit at its Indore formulations facility 86
Government and Public Interest 87
Sep 10, 2018: Understanding depression and related symptoms key to suicide prevention in SA 87
Product News 88
Feb 17, 2017: Cipla launches Hepatitis B vaccine in India 88
Other Significant Developments 89
Jun 26, 2018: Consumers need to understand the risks associated with using medication to combat pain 89
Jun 12, 2018: Cipla Quality Chemical Industries: Building capacity to mitigate the burden of cancer in Uganda 90
Appendix 91
Methodology 91
About GlobalData 91
Contact Us 91
Disclaimer 91
Cipla Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cipla Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cipla Ltd, Deals By Therapy Area, 2012 to YTD 2018 10
Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12
Cipla Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 13
Cipla and Aurobindo Acquires Certain Generic Products Rights in the US from Teva Pharma 17
Cipla Acquires Product Line from Camber Pharma 18
Cipla Acquires Marketing Rights for Skin Care Products from Percos India 19
Cipla to Acquire Manufacturing Facility in Goa from Okasa for USD4.8 Million 20
Cipla to Acquire Manufacturing Facility in Maharashtra from Okasa Pharma for USD12 Million 21
Cipla, Zydus Cadilla, Dr. Reddy’s Labs and Baring Asia May Acquire Bharat Serums and Vaccines 22
FIL Capital to Invest in Cipla Health 24
Cipla Enters into Marketing Partnership with Eli Lilly & Company (India) 25
MannKind to Enter into Marketing and Distribution Agreement with Cipla 26
Cipla and Roche Products Enter into Distribution Agreement 27
Cipla and Novartis May Enter into Co-Marketing Agreement 28
Cipla Enters into Distribution Agreement with BioQ Pharma 29
Cipla to Form Joint Venture with Biopharm 30
Cipla Enters into Distribution Agreement with Serum Institute 31
Cipla to Enter into Joint Venture Agreement with Cooper Pharma and PHI 32
Medicines for Malaria Venture Enters into Agreement with Cipla and Strides Arcolab 33
Cipla Enters into Distribution Agreement with Serum Institute of India 34
Medpro Pharma to Enter into Distribution Agreement with Teva Pharma 35
Cipla Enters into Agreement with S&D Pharma 36
Cipla Enters into Co-Marketing Agreement with BioQuiddity for OneDose ReadyfusOR 37
Cipla Enters into Co-Marketing Agreement with Hetero Drugs 38
Cipla Plans To Enters Into Co-Development Agreement With Aspen Pharmacare 39
Drugs for Neglected Diseases initiative Enters Into Agreement With Cipla To Develop Pediatric Antiretroviral Drug Combination 40
Cipla Receives Rights from MSN Laboratories 41
Cipla Enters into Licensing Agreement with Stempeutics 42
Cipla USA Enters into Licensing Agreement with MEDRx for MRX-4TZT 43
Cipla Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb Company 44
Cipla Amends Licensing Agreement with Medicines Patent Pool and Gilead Sciences 45
Aurobindo Pharma, Cipla, Desano Pharma, Emcure Pharma, Hetero Labs and Laurus Labs Enter into Licensing Agreement with Medicines Patent Pool 46
Cipla Amends Licensing Agreement with Salix Pharma for Rifaximin 47
Gilead Sciences Enters into Licensing Agreement with Cipla 48
Cipla Enters into Licensing Agreement with Medicines Patent Pool for HIV Medicines 49
Cipla Amends Licensing Agreement with Medicines Patent Pool and ViiV Healthcare 50
Cipla, Emcure Pharma, Hetero Drugs, Natco Pharma and Aurobindo Pharma Enter into Licensing Agreement with Medicines Patent Pool and Bristol-Myers Squibb 51
Cipla Enters Into Licensing Agreement With MSD Pharma For Raltegravir 52
Cipla Quality Chemical Industries Raises USD41.8 Million in IPO of Shares 54
Cipla to Raise USD293.2 Million in Public Offering of Securities 55
Cipla to Raise USD293.2 Million in Debt Offering 56
Cipla Medpro South Africa Acquires Mirren for USD33.2 Million 57
PharmaS to Acquire Cipla Croatia from Cipla Holding 58
Saba Investment to Sell 99% Stake in Al Jabal Drugs and Medical Appliances 59
Ascendis Health to Acquire 100% Stake in Cipla Agrimed Proprietary and Cipla Vet Proprietary 60
Allergan Acquires Chase Pharma 61
Cipla Acquires InvaGen Pharma and Exelan Pharma for USD550 Million 62
Cipla Divests 25% Stake in BioMab for USD25.8 Million 63
Cipla Acquires 51% Stake in Quality Chemicals for USD30 Million 64
Cipla to Acquire Duomed Produtos 65
Meditab to Sell 48.22% Stake in Jiangsu Cdymax for USD18.5 Million 66
Cipla Acquires Remaining 75% Stake in MabPharm 67
Cipla to Acquire 51% Stake in Yemen-Based Pharma Company for USD21 Million 68
Cipla (Mauritius) Acquires 60% Stake in Citihealth Imports for USD14 Million 69
Cipla Acquires Celeris, Medical Products Distributor 70
Cipla Acquires Additional 14.5% Stake In Quality Chemical Industries For US$15 Million 71
Cipla Completes Acquisition Of Cipla Medpro South Africa For US$512 Million 72
Cipla Sells Minority Stake In Desano, Maker Of Generic Products 74
Cipla Ltd, Key Competitors 75
Cipla Ltd, Key Employees 76
Cipla Ltd, Subsidiaries 77
List of Figures
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Cipla Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Cipla Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Cipla Ltd, Medical Devices Deals, 2012 to YTD 2018 12